A single Bitcoin short position worth $8.6 million was liquidated on the OKX exchange at a price of $83,118 on October 19. This liquidation involved a perpetual futures contract and was recorded as an individual transaction, not reflecting total liquidations on the platform. The event highlights the volatility and risk involved in trading Bitcoin futures, especially with large leveraged positions. Such liquidations can impact market sentiment and price movements in the short term.
A single $8.6 million Bitcoin short position was liquidated on OKX at a price of $83,118, illustrating the high volatility in Bitcoin futures trading. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 19, 2026 15:02 WIB: out of 50 major cryptocurrencies priced on Pluang, 41 rose and 8 fell today. Notable moves include LINK at Rp220.262 with a 1-day change of +2.33% and a Pluang order activity split of 64% Sell / 36% Buy, ENJ at Rp491 down 2.15% with 95% Sell / 5% Buy activity, and FTM at Rp11.382 down 2.05%, with typical hold times ranging from 63 to 105 days.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
